Neonatal Respiratory FailureFlow&GrowNCT06123143
Flow and Grow - The Ideal Time to Wean CPAP Off In Extremely Low Birth Weight Infants
A study testing Standardized/structured CPAP weaning protocol in people with Neonatal Respiratory Failure, run by University of California, San Diego at 5 sites in United States.
Trial summary
Preterm neonates born at less than 30 weeks' gestation are commonly maintained on invasive or non-invasive respiratory support to facilitate gas exchange. While non-invasive respiratory support (NIS) can be gradually reduced over time as the infant grows, most weaning strategies often lead to weaning failure. Read more about this study
- Who is it for?
- Ages Up to 30 weeks
- Conditions the study is for
- Neonatal Respiratory Failure
- What is being tested?
- Standardized/structured CPAP weaning protocol
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 5 sitesUnited States
- Study dates
- 27 Nov 2023to Nov 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 30 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- All infants admitted to the NICU at Jacobs, Rancho Springs, Scripps La Jolla, Rady Children's Hospital, or Palomar born at < 30 weeks CGA
- Informed parental consent obtained
Who cannot join
- Declined or unable to give informed consent
- Infants with known congenital anomalies or complications that require long term support (pulmonary hypoplasia, airway defects, genetic syndromes, necrotizing enterocolitis (NEC), spontaneous intestinal perforation (SIP), anything surgical)
- Intubated for over 4 weeks of life (28 days)
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
Palomar Medical Center Rady NICU
Escondido, California, 92029
Sandra Leibel, MD, 858-249-1702, saleibel@health.ucsd.edu
Sarah Lazar, MPH, 858-249-1711, slazar@health.ucsd.edu
- Recruiting
Scripps La Jolla Rady NICU
La Jolla, California, 92037
Sandra Leibel, MD, saleibel@health.ucsd.edu
Sarah Lazar, MPH, 858-249-1711, slazar@health.ucsd.edu
- Recruiting
University of California, San Diego Jacobs Medical Center
La Jolla, California, 92037
Sandra Leibel, MD, saleibel@health.ucsd.edu
Sarah Lazar, MPH, 858-249-1711, slazar@health.ucsd.edu
- Recruiting
Rancho Springs Medical Center Rady NICU
Murrieta, California, 92562
Sandra Leibel, MD, saleibel@health.ucsd.edu
Sarah Lazar, MPH, 858-249-1711, slazar@health.ucsd.edu
- Recruiting
Rady Children's Hospital-San Diego
San Diego, California, 92123
Sandra Leibel, MD, saleibel@health.ucsd.edu
Sarah Lazar, MPH, 858-576-1700 ext. 223209, slazar@health.ucsd.edu
About this study
Official title: Flow and Grow - A CPAP Management Strategy for Preterm Infants to Support Lung Growth. A Randomized, Prospective, Multi-center Study
Preterm neonates born at less than 30 weeks' gestation are commonly maintained on invasive or non-invasive respiratory support to facilitate gas exchange. While non-invasive respiratory support (NIS) can be gradually reduced over time as the infant grows, most weaning strategies often lead to weaning failure. This failure is evidenced by an increase in significant events such as apneas, desaturations, and/or bradycardias, increased work of breathing, or an inability to oxygenate or ventilate, resulting in escalated respiratory support. Although the optimal approach to weaning NIS remains uncertain, neonatal units that delay Continuous Positive Airway Pressure (CPAP) weaning until 32-34 weeks corrected gestational age exhibit lower rates of chronic lung disease. Therefore, the investigators aim to compare the duration on respiratory support and oxygen exposure in infants born at less than 30 weeks' gestational age who undergo a structured weaning protocol that includes remaining on CPAP until at least 32-34 weeks corrected gestational age (CGA). The hypothesis posits that preterm infants following a structured weaning protocol, including maintaining CPAP until a specific gestational age, will demonstrate lower rates of weaning failure off CPAP (defined as requiring more support and/or experiencing increased stimulation events 72 hours after CPAP weaning) than those managed according to the medical team's discretion.
Read the detailed description
This is a multicenter, non-blinded, randomized control trial involving premature neonates born between 23 0/7 and 29 6/7 weeks gestational age. The trial will take place in five Neonatal Intensive Care Units (NICUs) within the Rady Children's/University of California, San Diego network, including Rady Children's Hospital - San Diego, Jacobs Medical Center, Scripps La Jolla (Rady NICU), Rancho Springs (Rady NICU), and Palomar (Rady NICU). The investigators aim to recruit 130 infants, a target sample size determined based on retrospective data from all of the participating units.
Examination of CPAP failure rates in babies < 28 weeks who were weaned off CPAP before 34 weeks CGA revealed a 62.5% failure rate, whereas those who remained on CPAP at or beyond 34 weeks exhibited a 26.7% failure rate. Thus, the investigators selected 34 weeks CGA as the time point for maintaining CPAP in babies < 28 weeks GA. For infants > 28 weeks, the retrospective review demonstrated a 76% failure rate if weaned off CPAP before 32 weeks, while those who remained on CPAP at or beyond 32 weeks showed an 11% failure rate. Consequently, the investigators chose 32 weeks CGA as the designated time point for continuing CPAP in babies with a GA of 28-30 weeks.
The sample size calculation employed a two-independent- study-group design with a primary endpoint of a binomial outcome (failed CPAP wean, yes/no). The investigators set the alpha error rate at 0.05 and power at 80%. To achieve a 50% reduction in the CPAP weaning failure rate, they aimed to enroll a total of 80 infants < 28 weeks and 50 infants 28-30 weeks (130 infants in total).
Consent will be obtained after the eligible infant has been extubated or has been stable on NIS (defined as CPAP/NIMV/NIPPV- all modes of pressure reliant respiratory support) for over 72 hours. NIS is delivered via occlusive (Fischer \& Paykel [F\&P]) or non-occlusive (RAM TM/Nioflo TM) interfaces at any pressure and oxygen need.
A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean) while the control group (routine care) will undergo weaning based on unit-specific practices. All infants in the treatment group will remain on CPAP until either 32 or 34 weeks CGA, depending on their GA age at birth. Infants born at 27 6/7 weeks or less will continue on CPAP until at least 34 weeks CGA if they are in the treatment group, whereas infants born at 28 0/7 to 29 6/7 will stay on CPAP until at least 32 weeks in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RN) and respiratory therapists (RT), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices. According to the retrospective chart review, no standardized weaning practices have been identified at any of the sites, with decisions primarily driven by the medical team caring for the infant.
The treatment group algorithm will contain the following features:
◦ The algorithm will specify the type of NIS to use, outline how to assess the infant every 24 hours, and provide guidance on whether to wean, maintain, or increase support based on the following 3 questions:
Within the last 24 hours:
- Has the FiO2 been less than 30%?
- Has there been weight gain?
- Have there been no significant events necessitating stimulation unrelated to feeding?
If the answer is 'yes' to all 3 questions, the provider can begin to wean the infant according to the algorithm's recommendations. If the answer to any of the questions is 'no', the NIS will be maintained. In the event of clinical instability, the support can be increased.
- The FiO2 should be titrated based on CGA parameters
- All babies should initially be extubated/maintained on occlusive CPAP (F\&P). Proper placement of the interface is essential, and a video demonstrating accurate interface placement is provided. It is crucial to ensure that the prongs are positioned 2mm from the septum and the mask is the proper size. They should be alternated every 6 hours if that's the unit policy and the nose should be monitored for breakdown. Appropriate barriers should be applied. If the FiO2 is more than 10-20% above the baseline, if the number of stimulation events increase, and/or there is increased work of breathing, the MD/NNP should be notified. The RT and RN should refer to the Keep the PEEP algorithm (algorithms will be available at the bedside for staff reference).
- For non-occlusive CPAP, the RAM or Nioflo cannula, or equivalent can be used. The team may transition the infant to non-occlusive NIS if there is a pressure wound despite changes in the F\&P interface, or if the occlusive CPAP is set at a PEEP of 7 or lower. Consider transitioning infants to non-occlusive NIS if they are over 30 weeks and not on NIMV/NIPPV. Increase the PEEP by 1-2 from the transition from occlusive to non-occlusive NIS.
- In cases of nasal breakdown, if breakdown is identified, the occlusive CPAP interface should be changed (mask to mask, mask to prongs) to reduce pressure on the wound as per unit policy. If necessary, the wound team should be contacted, and a barrier and therapeutic cream should be applied.
- To address issues with chin straps, pacifiers, or hands, the chin strap or hands should be placed under the chin, or the pacifier should be inserted into the mouth if it is open, resulting in loss of PEEP and/or worsening oxygenation/ventilation. The need for the chin strap should be reassessed every 6 hours. Ensure that the chin strap is appropriately positioned from the parietal-occipital part of scalp to the mandible (a video demonstrating proper placement will be provided), securing it so that the mouth is passively closed but the infant can still yawn and cry.
- Conditions
- Neonatal Respiratory Failure
- Being tested
- Standardized/structured CPAP weaning protocol
- Keywords
- Neonatal, CPAP
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standardized/structured CPAP weaning protocolOther
Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
| Study group | Role | What they receive |
|---|---|---|
| Standardized NIS Wean | Experimental | A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean). All infants in the treatment group will remain on NIS until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on NIS until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on NIS until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices. Receives: Other: Standardized/structured CPAP weaning protocol |
| Control | No intervention | Babies in the control group (non-standardized wean) will be weaned based on unit specific practices. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with CPAP/NIS weaning failure
Number of participants needing more support and/or with increased sleep stimulation events after weaning off of CPAP/NIS.
Measured: 72 hours after weaning off of CPAP
Secondary outcomes (16)
Number of stimulation events per 24 hours
Significant results are defined as: apnea (pause in respiration for greater than 20 seconds), and/or bradycardia (heart rate < 100) and/or desaturations (pulse oximetry saturations < 85%) not associated with feeds.
Measured: Through study completion, an average of 4 months
Length of hospital stay
Length of hospital stay prior to discharge home, including days at transfer hospital (if applicable).
Measured: Through study completion, an average of 4 months
Rate of bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) assessed at 36 weeks gestational age.
Measured: Through study completion, an average of 4 months
Use of postnatal steroids
Use of postnatal steroids during the NICU course
Measured: Through study completion, an average of 4 months
Use of antibiotics
Use of antibiotics during the NICU course
Measured: Through study completion, an average of 4 months
Number of participants with a need for re-intubation
Number of participants with a need for re-intubation by birth weight strata (< 750g; 750g - 999g) after enrollment in study
Measured: Through study completion, an average of 4 months
Total duration of positive pressure respiratory support
Total duration of positive pressure respiratory support (up to the time of discharge from the NICU)
Measured: Through study completion, an average of 4 months
Number of participants requiring supplemental oxygen
Total time of supplemental oxygen until discharge.
Measured: Through study completion, an average of 4 months
Number of participants experiencing pulmonary air leaks
Number of participants experiencing pulmonary air leaks identified radiologically by a masked pediatric radiologist.
Measured: Through study completion, an average of 4 months
Number of participants with nasal deformities
Number of participants with nasal deformities, as defined by Robinson et al.
Measured: Through study completion, an average of 4 months
Time to establish full tube feeds
Time to establish full feeds (no longer requiring parenteral nutrition)
Measured: Through study completion, an average of 4 months
Time to establish full oral feeds
Feeding performance, including number of days to reach full oral feeds (defined as tolerating oral feeds without any requirement for intravenous fluids or nasogastric/orogastric feeds for >24 hours) and type of feeds (breastfeeding, bottle feeding or both).
Measured: Through study completion, an average of 4 months
Number of participants with nosocomial infections
Number of participants with nosocomial infections, defined as positive blood culture, positive CSF culture and/or diagnosis of pneumonia.
Measured: Through study completion, an average of 4 months
Number of participants with intraventricular haemorrhage (IVH) grade III-IV and/or periventricular leukomalacia (PVL) and/or ventriculomegaly on cranial ultrasound.
IVH will be analyzed using a head ultrasound and the grade will be determined by the radiologist
Measured: Through study completion, an average of 4 months
Number of participants with retinopathy of prematurity (ROP)
Retinopathy of prematurity (ROP) at routine ophthalmological examination beginning at 32 weeks gestational age; graded according to the international classification, as stage 3 (fibrovascular proliferation), stage 4 (partial retinal detachment) and stage 5 (total retinal detachment).
Measured: Through study completion, an average of 4 months
Rate of weight gain
Weight gain from birth to hospital discharge, weight gain from start of study to end of study,
Measured: Through study completion, an average of 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2023
- Study start27 Nov 2023
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neonatal Respiratory FailureStudies of the same condition, open and under way.
- More trials run by University of California, San DiegoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean), while the control group (routine care) will undergo weaning based on unit-specific practices. All infants in the treatment group will remain on CPAP until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on CPAP until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on CPAP until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices.
- Masking
- None (open label)
- Enrolment
- 130 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Diego
- Sponsor type
- University, hospital or other
- Collaborators
- Rady Children's Hospital, San Diego
- Responsible party
- Principal investigator, Sandra Leibel, University of California, San Diego
- Investigators
- Sandra Leibel, MD, Principal investigator, University of California, San Diego
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06123143
- Sponsor's protocol ID
- 807423
- Acronym
- Flow&Grow
- Status last verified
- Jan 2026
- First submitted
- 19 Sep 2023
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data (IPD) will be made available upon study completion per International Committee of Medical Journal Editors (ICMJE) policy. The data sharing plan will include all IPD that underlie the reported results, after deidentification (text, tables, figures, appendices). Additional documents to be made available will be the study protocol, statistical analysis plan, and informed consent form. Data will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Flow and Grow - A CPAP Management Strategy for Preterm Infants to Support Lung Growth. A Randomized, Prospective, Multi-center Study
- ClinicalTrials.gov ID
- NCT06123143
- Acronym / sponsor ID
- Flow&Grow / 807423
- Conditions
- Neonatal Respiratory Failure
- Keywords
- Neonatal, CPAP
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 130 participants (estimated)
- Lead sponsor
- University of California, San DiegoUniversity, hospital or other
- Collaborators
- Rady Children's Hospital, San Diego
- Study start
- 27 Nov 2023 (actual)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 8 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Preterm neonates born at less than 30 weeks' gestation are commonly maintained on invasive or non-invasive respiratory support to facilitate gas exchange. While non-invasive respiratory support (NIS) can be gradually reduced over time as the infant grows, most weaning strategies often lead to weaning failure. This failure is evidenced by an increase in significant events such as apneas, desaturations, and/or bradycardias, increased work of breathing, or an inability to oxygenate or ventilate, resulting in escalated respiratory support. Although the optimal approach to weaning NIS remains uncertain, neonatal units that delay Continuous Positive Airway Pressure (CPAP) weaning until 32-34 weeks corrected gestational age exhibit lower rates of chronic lung disease. Therefore, the investigators aim to compare the duration on respiratory support and oxygen exposure in infants born at less than 30 weeks' gestational age who undergo a structured weaning protocol that includes remaining on CPAP until at least 32-34 weeks corrected gestational age (CGA). The hypothesis posits that preterm infants following a structured weaning protocol, including maintaining CPAP until a specific gestational age, will demonstrate lower rates of weaning failure off CPAP (defined as requiring more support and/or experiencing increased stimulation events 72 hours after CPAP weaning) than those managed according to the medical team's discretion.
Detailed description
This is a multicenter, non-blinded, randomized control trial involving premature neonates born between 23 0/7 and 29 6/7 weeks gestational age. The trial will take place in five Neonatal Intensive Care Units (NICUs) within the Rady Children's/University of California, San Diego network, including Rady Children's Hospital - San Diego, Jacobs Medical Center, Scripps La Jolla (Rady NICU), Rancho Springs (Rady NICU), and Palomar (Rady NICU). The investigators aim to recruit 130 infants, a target sample size determined based on retrospective data from all of the participating units.
Examination of CPAP failure rates in babies < 28 weeks who were weaned off CPAP before 34 weeks CGA revealed a 62.5% failure rate, whereas those who remained on CPAP at or beyond 34 weeks exhibited a 26.7% failure rate. Thus, the investigators selected 34 weeks CGA as the time point for maintaining CPAP in babies < 28 weeks GA. For infants > 28 weeks, the retrospective review demonstrated a 76% failure rate if weaned off CPAP before 32 weeks, while those who remained on CPAP at or beyond 32 weeks showed an 11% failure rate. Consequently, the investigators chose 32 weeks CGA as the designated time point for continuing CPAP in babies with a GA of 28-30 weeks.
The sample size calculation employed a two-independent- study-group design with a primary endpoint of a binomial outcome (failed CPAP wean, yes/no). The investigators set the alpha error rate at 0.05 and power at 80%. To achieve a 50% reduction in the CPAP weaning failure rate, they aimed to enroll a total of 80 infants < 28 weeks and 50 infants 28-30 weeks (130 infants in total).
Consent will be obtained after the eligible infant has been extubated or has been stable on NIS (defined as CPAP/NIMV/NIPPV- all modes of pressure reliant respiratory support) for over 72 hours. NIS is delivered via occlusive (Fischer \& Paykel [F\&P]) or non-occlusive (RAM TM/Nioflo TM) interfaces at any pressure and oxygen need.
A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean) while the control group (routine care) will undergo weaning based on unit-specific practices. All infants in the treatment group will remain on CPAP until either 32 or 34 weeks CGA, depending on their GA age at birth. Infants born at 27 6/7 weeks or less will continue on CPAP until at least 34 weeks CGA if they are in the treatment group, whereas infants born at 28 0/7 to 29 6/7 will stay on CPAP until at least 32 weeks in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RN) and respiratory therapists (RT), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices. According to the retrospective chart review, no standardized weaning practices have been identified at any of the sites, with decisions primarily driven by the medical team caring for the infant.
The treatment group algorithm will contain the following features:
◦ The algorithm will specify the type of NIS to use, outline how to assess the infant every 24 hours, and provide guidance on whether to wean, maintain, or increase support based on the following 3 questions:
Within the last 24 hours:
- Has the FiO2 been less than 30%?
- Has there been weight gain?
- Have there been no significant events necessitating stimulation unrelated to feeding?
If the answer is 'yes' to all 3 questions, the provider can begin to wean the infant according to the algorithm's recommendations. If the answer to any of the questions is 'no', the NIS will be maintained. In the event of clinical instability, the support can be increased.
- The FiO2 should be titrated based on CGA parameters
- All babies should initially be extubated/maintained on occlusive CPAP (F\&P). Proper placement of the interface is essential, and a video demonstrating accurate interface placement is provided. It is crucial to ensure that the prongs are positioned 2mm from the septum and the mask is the proper size. They should be alternated every 6 hours if that's the unit policy and the nose should be monitored for breakdown. Appropriate barriers should be applied. If the FiO2 is more than 10-20% above the baseline, if the number of stimulation events increase, and/or there is increased work of breathing, the MD/NNP should be notified. The RT and RN should refer to the Keep the PEEP algorithm (algorithms will be available at the bedside for staff reference).
- For non-occlusive CPAP, the RAM or Nioflo cannula, or equivalent can be used. The team may transition the infant to non-occlusive NIS if there is a pressure wound despite changes in the F\&P interface, or if the occlusive CPAP is set at a PEEP of 7 or lower. Consider transitioning infants to non-occlusive NIS if they are over 30 weeks and not on NIMV/NIPPV. Increase the PEEP by 1-2 from the transition from occlusive to non-occlusive NIS.
- In cases of nasal breakdown, if breakdown is identified, the occlusive CPAP interface should be changed (mask to mask, mask to prongs) to reduce pressure on the wound as per unit policy. If necessary, the wound team should be contacted, and a barrier and therapeutic cream should be applied.
- To address issues with chin straps, pacifiers, or hands, the chin strap or hands should be placed under the chin, or the pacifier should be inserted into the mouth if it is open, resulting in loss of PEEP and/or worsening oxygenation/ventilation. The need for the chin strap should be reassessed every 6 hours. Ensure that the chin strap is appropriately positioned from the parietal-occipital part of scalp to the mandible (a video demonstrating proper placement will be provided), securing it so that the mouth is passively closed but the infant can still yawn and cry.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean), while the control group (routine care) will undergo weaning based on unit-specific practices. All infants in the treatment group will remain on CPAP until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on CPAP until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on CPAP until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices.
| Arm | Type | Receives |
|---|---|---|
| Standardized NIS Wean | Experimental | Other: Standardized/structured CPAP weaning protocolA standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean). All infants in the treatment group will remain on NIS until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on NIS until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on NIS until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices. |
| Control | No intervention | –Babies in the control group (non-standardized wean) will be weaned based on unit specific practices. |
Who may qualify
- Ages
- Up to 30 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- All infants admitted to the NICU at Jacobs, Rancho Springs, Scripps La Jolla, Rady Children's Hospital, or Palomar born at < 30 weeks CGA
- Informed parental consent obtained
Key exclusion criteria (3 listed)
- Declined or unable to give informed consent
- Infants with known congenital anomalies or complications that require long term support (pulmonary hypoplasia, airway defects, genetic syndromes, necrotizing enterocolitis (NEC), spontaneous intestinal perforation (SIP), anything surgical)
- Intubated for over 4 weeks of life (28 days)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standardized/structured CPAP weaning protocolStandardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA. | Other | Standardized NIS Wean |
Primary outcome
Number of participants with CPAP/NIS weaning failure
Time frame: 72 hours after weaning off of CPAP
Number of participants needing more support and/or with increased sleep stimulation events after weaning off of CPAP/NIS.
16 secondary outcomes
Number of stimulation events per 24 hours
Time frame: Through study completion, an average of 4 months
Length of hospital stay
Time frame: Through study completion, an average of 4 months
Rate of bronchopulmonary dysplasia
Time frame: Through study completion, an average of 4 months
Use of postnatal steroids
Time frame: Through study completion, an average of 4 months
Use of antibiotics
Time frame: Through study completion, an average of 4 months
Number of participants with a need for re-intubation
Time frame: Through study completion, an average of 4 months
Total duration of positive pressure respiratory support
Time frame: Through study completion, an average of 4 months
Number of participants requiring supplemental oxygen
Time frame: Through study completion, an average of 4 months
Number of participants experiencing pulmonary air leaks
Time frame: Through study completion, an average of 4 months
Number of participants with nasal deformities
Time frame: Through study completion, an average of 4 months
Time to establish full tube feeds
Time frame: Through study completion, an average of 4 months
Time to establish full oral feeds
Time frame: Through study completion, an average of 4 months
Number of participants with nosocomial infections
Time frame: Through study completion, an average of 4 months
Number of participants with intraventricular haemorrhage (IVH) grade III-IV and/or periventricular leukomalacia (PVL) and/or ventriculomegaly on cranial ultrasound.
Time frame: Through study completion, an average of 4 months
Number of participants with retinopathy of prematurity (ROP)
Time frame: Through study completion, an average of 4 months
Rate of weight gain
Time frame: Through study completion, an average of 4 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: Yes. Individual participant data (IPD) will be made available upon study completion per International Committee of Medical Journal Editors (ICMJE) policy. The data sharing plan will include all IPD that underlie the reported results, after deidentification (text, tables, figures, appendices). Additional documents to be made available will be the study protocol, statistical analysis plan, and informed consent form. Data will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.
Related trials for Neonatal Respiratory Failure
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Recruiting
REspiratory MEchanics for Delivering Individualised Exogenous Surfactant
Respiratory Distress Syndrome in Premature Infant
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingObservational study
Respiratory Progression in Adults With Duchenne Muscular Dystrophy.
Duchenne Muscular Dystrophy (DMD), Respiratory Function Decline
Active, not recruiting
Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants
IVH- Intraventricular Hemorrhage, Extreme Prematurity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sandra Leibel, MD principal investigator
University of California, San Diego
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standardized/structured CPAP weaning protocol in people with Neonatal Respiratory Failure, run by University of California, San Diego at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sandra Leibel, MD (858-249-1702, saleibel@health.ucsd.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with CPAP/NIS weaning failure (time frame: 72 hours after weaning off of CPAP). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.